List of Xofluza drug patents

Xofluza is owned by Genentech Inc.

Xofluza contains Baloxavir Marboxil.

Xofluza has a total of 8 drug patents out of which 0 drug patents have expired.

Xofluza was authorised for market use on 24 October, 2018.

Xofluza is available in tablet;oral dosage forms.

Xofluza can be used as method for treating influenza; method for post-exposure prophylaxis of influenza, method for post-exposure prophylaxis of influenza; method for treating influenza.

Drug patent challenges can be filed against Xofluza from October, 2022.

The generics of Xofluza are possible to be released after 25 September, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8987441 GENENTECH INC Substituted polycyclic carbamoyl pyridone derivative prodrug
Sep, 2031

(8 years from now)

US10392406 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(13 years from now)

US10759814 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815835 GENENTECH INC Substituted polycyclic carbamolypyridone derivative
Jun, 2030

(7 years from now)

US8927710 GENENTECH INC Substituted polycyclic carbamoylpyridone derivative
May, 2031

(8 years from now)

US10633397 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(13 years from now)

US11306106 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(14 years from now)

US11261198 GENENTECH INC Process for preparing substituted polycyclic pyridone derivative and crystal thereof
Sep, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 16, 2022
New Chemical Entity Exclusivity (NCE) Oct 24, 2023

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 24 October, 2018

Treatment: Method for post-exposure prophylaxis of influenza; Method for treating influenza

Dosage: TABLET;ORAL

How can I launch a generic of XOFLUZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in